Market Spotlight: Atrial Fibrillation
Market Spotlight: Atrial Fibrillation
$1,318.00
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2018, there were approximately 47.2 million prevalent cases of atrial fibrillation worldwide, and forecasts that number to increase to 56.7 million prevalent cases by 2027.
- The approved drugs in the atrial fibrillation/flutter space focus on targets such as beta adrenergic receptors, alpha adrenergic receptors, potassium channels, sodium channels, and calcium channel. The majority of marketed drugs are administered via the intravenous or oral routes, with only one product being available in a transdermal formulation.
- The approved drugs in the stroke prevention in atrial fibrillation (SPAF) space focus on targets such as coagulation factor X, adenosine diphosphate P2Y12 receptor, and thrombin (coagulation factor IIa). All of the marketed drugs for SPAF are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for atrial fibrillation/flutter are in Phase II, with one drug in the NDA/BLA phase.
- Therapies in development for atrial fibrillation/flutter focus on targets such as potassium channels, sodium channels, and beta adrenergic receptors. The majority of these drugs are administered via the oral route, with the remainder being tested in intravenous and inhaled formulations.
- The only industry-sponsored drug in active clinical development for SPAF is in Phase II.
- The only therapy in development for SPAF targets coagulation factor XI. It is administered via the subcutaneous route.
- The only high-impact upcoming event in the atrial fibrillation/flutter space is topline Phase II trial results for InRhythm.
- The only high-impact upcoming event in the SPAF space is topline Phase III trial results for Savaysa. The overall likelihood of approval of a Phase I atrial fibrillation/flutter asset is 2.4%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 12.0 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.
- The overall likelihood of approval of a Phase I SPAF asset is 9.8%, and the average probability a drug advances from Phase III is 85.7%. Drugs, on average, take 6.2 years from Phase I to approval, compared to 9.3 years in the overall hematology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for atrial fibrillation have been in the late phases of development, with 76% of trials in Phase III–IV, and only 24% in Phase I–II.
- The US leads in terms of the number of atrial fibrillation clinical trials globally, while Germany leads the major European markets. Clinical trial activity in the atrial fibrillation space is dominated by completed trials. Bayer has the highest number of completed clinical trials for atrial fibrillation, with 40 trials.
- Bayer leads industry sponsors with the highest overall number of clinical trials for atrial fibrillation, followed by Johnson & Johnson.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Risk factors
8 Diagnosis
8 Patient segmentation
10 TREATMENT
10 Rate control strategy
10 Rhythm control strategy
11 Medications to prevent thromboembolism
14 EPIDEMIOLOGY
17 MARKETED DRUGS
17 Atrial fibrillation/flutter
20 SPAF
22 PIPELINE DRUGS
22 Atrial fibrillation/flutter
25 SPAF
29 RECENT EVENTS AND ANALYST OPINION
29 Brinavess for Atrial Fibrillation/Flutter (December 24, 2019)
30 Brinavess for Atrial Fibrillation/Flutter (December 10, 2019)
33 Brinavess for Atrial Fibrillation/Flutter (December 6, 2019)
35 Parasym Device for Atrial Fibrillation/Flutter (May 9, 2019)
36 eMURMUR ID for Atrial Fibrillation/Flutter (May 7, 2019)
37 HeartLight Endoscopic Ablation System for Atrial Fibrillation/Flutter (March 25, 2019)
39 Apple Watch for Atrial Fibrillation/Flutter (March 16, 2019)
40 MAA868 for SPAF (February 27, 2019)
41 KEY UPCOMING EVENTS
41 Atrial fibrillation/flutter
41 SPAF
42 KEY REGULATORY EVENTS
42 Eko’s AI Algorithm To Detect Heart Conditions Cleared By US FDA
42 Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
42 Brinavess Rejected By Advisory Cmte., Leaving US FDA To Mull Lifting Clinical Hold On Correvio’s AFib Drug
42 Brinavess’ US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug
43 Brinavess To Have An Advisory Committee Review
44 PROBABILITY OF SUCCESS
44 Atrial fibrillation/flutter
44 SPAF
46 LICENSING AND ASSET ACQUISITION DEALS
46 Attune Gets Exclusive Rights To Stanford IP
46 Verily And iRhythm Agree To Collaborate On Atrial Fibrillation
46 AtriCure Adds Lariat LAA Closure System With $300M SentreHeart Acquisition
47 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
55 BIBLIOGRAPHY
56 Prescription information
57 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in prevalent cases of atrial fibrillation, 2018–27
22 Figure 2: Overview of pipeline drugs for atrial fibrillation/flutter in the US
22 Figure 3: Pipeline drugs for atrial fibrillation/flutter, by company
23 Figure 4: Pipeline drugs for atrial fibrillation/flutter, by drug type
23 Figure 5: Pipeline drugs for atrial fibrillation/flutter, by classification
25 Figure 6: Overview of pipeline drugs for SPAF in the US
25 Figure 7: Pipeline drugs for SPAF, by company
26 Figure 8: Pipeline drugs for SPAF, by drug type
26 Figure 9: Pipeline drugs for SPAF, by classification
41 Figure 10: Key upcoming events for atrial fibrillation/flutter
41 Figure 11: Key upcoming events for SPAF
44 Figure 12: Probability of success in the atrial fibrillation/flutter pipeline
45 Figure 13: Probability of success in the SPAF pipeline
49 Figure 14: Clinical trials in atrial fibrillation
49 Figure 15: Top 10 drugs for clinical trials in atrial fibrillation
50 Figure 16: Top 10 companies for clinical trials in atrial fibrillation
50 Figure 17: Trial locations in atrial fibrillation
51 Figure 18: Atrial fibrillation trials status
52 Figure 19: Atrial fibrillation trials sponsors, by phase
LIST OF TABLES
15 Table 1: Prevalent cases of atrial fibrillation, 2018–27
18 Table 2: Marketed drugs for atrial fibrillation/flutter
21 Table 3: Marketed drugs for SPAF
24 Table 4: Pipeline drugs for atrial fibrillation/flutter in the US
27 Table 5: Pipeline drugs for SPAF in the US
29 Table 6: Brinavess for Atrial Fibrillation/Flutter (December 24, 2019)
30 Table 7: Brinavess for Atrial Fibrillation/Flutter (December 10, 2019)
34 Table 8: Brinavess for Atrial Fibrillation/Flutter (December 6, 2019)
35 Table 9: Parasym Device for Atrial Fibrillation/Flutter (May 9, 2019)
37 Table 10: eMURMUR ID for Atrial Fibrillation/Flutter (May 7, 2019)
38 Table 11: HeartLight Endoscopic Ablation System for Atrial Fibrillation/Flutter (March 25, 2019)
39 Table 12: Apple Watch for Atrial Fibrillation/Flutter (March 16, 2019)
40 Table 13: MAA868 for SPAF (February 27, 2019)
47 Table 14: Historical global sales, by drug ($m), 2015-19
48 Table 15: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Polycystic Ovary Syndrome (PCOS) 
Sign up to the